Vision Financial Markets’s Matinas BioPharma MTNB Stock Holding History

Vision Financial Markets’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26	Hold	40	–	–	﹤0.01%	406
2026 Q1	$20	Hold	40	–	–	﹤0.01%	419
2025 Q4	$24	Hold	40	–	–	﹤0.01%	403
2025 Q3	$76	Hold	40	–	–	﹤0.01%	421
2025 Q2	$36	Hold	40	–	–	﹤0.01%	428
2025 Q1	$21	Buy	+40	New	+$24	﹤0.01%	429

Other funds holding MTNB

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HIW

Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

Vision Financial Markets's MTNB Position: Q2 2026 in Review

Vision Financial Markets held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 40 shares worth $26. The position accounts for ﹤0.01% of the portfolio, ranked #406.

Vision Financial Markets first reported a position in MTNB in Q1 2025 and has held it in 6 quarters since. The position peaked at $76 in Q3 2025. 25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

Vision Financial Markets held 40 shares of Matinas BioPharma worth $26 as of Q2 2026.
Vision Financial Markets left its Matinas BioPharma share count unchanged in Q2 2026.
Matinas BioPharma made up ﹤0.01% of Vision Financial Markets's portfolio in Q2 2026, its #406 holding.
Vision Financial Markets first reported a position in Matinas BioPharma in Q1 2025 and has held it in 6 quarters since.
Vision Financial Markets's Matinas BioPharma position peaked at $76 in Q3 2025.
25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on Vision Financial Markets's 13F filing for Q2 2026, filed 24 Jul 2026.